The present invention discloses anthraquinone compound according to Formula (1) or its pharmaceutical acceptable salts, prodrug and solvates thereof for use in suppressing the expression of mutated KRAS and mutated p53 genes in colorectal cancer cell. In a specific embodiment, the anthraquinone compound according to Formula (1) is also generally named with the chemical compund name of morindone. The anthraquinone compound according to Formula (1) is able to suppress the expression of mutated KRAS and mutated p53 genes of the colorectal cancer cell to prevent the colorectal cancer cells therapies resistance and poor prognosis.